• Greater than or equal to 97% of DNA removed
• Intact acellular framework
• Structural support for cells
• 10-6 sterility assurance level
• Room temperature storage
• Ready-to-use

DermACELL AWM® is used in the treatment of chronic non-healing wounds such as diabetic foot ulcers.

Contraindications include, but are not limited to use in any patient who has a known or suspected allergy to any of the antibiotics and/or processing reagents used. Please refer to DermACELL AWM®'s instructions for use (IFU).

The same medical/surgical conditions or complications that apply to any surgical procedure may occur during or following implantation. The surgeon is responsible for informing the patient of the risks associated with their treatment and the possibility of complications or adverse reactions. As with any allograft bio-implant, the potential for transmission of infections agents exists. Please refer to DermACELL AWM®'s IFU.

Potential adverse events or outcomes include, but are not limited to, infection, allograft tissue rejection, allergic reaction to residual processing reagents, loss of bio-implant structural integrity and reoperation. Please refer to DermACELL AWM®'s IFU.

The distributor, intermediary and/or end-user clinician or facility is responsible for storing decellularized dermis under appropriate conditions prior to further distribution or implantation. Dermis must be stored at room temperature (15°C to 30°C). Do not freeze or refrigerate. Minimize excessive exposure to light and protect from excessive heat.